Key Points
- CEO Laura Francis sold 25,972 SiBone shares at an average price of $20.12, generating approximately $522,557. After the transaction, she directly owned 291,491 shares, an 8.18% reduction in her stake.
- SiBone recently beat quarterly expectations, reporting an adjusted loss of $0.09 per share versus the $0.15 consensus loss and revenue of $56.01 million. Analysts maintain a “Moderate Buy” consensus with an average price target of $24.17.
- Institutional ownership remains high at 98.11%, with several investment firms substantially increasing their positions during recent quarters.
SiBone (NASDAQ:SIBN - Get Free Report) insider Anshul Maheshwari sold 11,636 shares of the business's stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $20.11, for a total value of $233,999.96. Following the transaction, the insider owned 223,284 shares of the company's stock, valued at $4,490,241.24. This trade represents a 4.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Anshul Maheshwari also recently made the following trade(s):
- On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $224,784.56.
- On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The stock was sold at an average price of $19.55, for a total value of $112,353.85.
- On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The stock was sold at an average price of $18.65, for a total value of $87,002.25.
- On Thursday, July 2nd, Anshul Maheshwari sold 3,317 shares of SiBone stock. The shares were sold at an average price of $16.77, for a total value of $55,626.09.
SiBone Stock Performance
Shares of SiBone stock opened at $19.43 on Thursday. The stock's fifty day moving average is $17.74 and its two-hundred day moving average is $15.40. The company has a market capitalization of $861.70 million, a PE ratio of -57.15 and a beta of 0.66. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. SiBone has a 52 week low of $11.48 and a 52 week high of $21.89.
SiBone (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.06. The business had revenue of $56.01 million during the quarter, compared to the consensus estimate of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. As a group, analysts expect that SiBone will post -0.4 earnings per share for the current year.
Hedge Funds Weigh In On SiBone
Institutional investors have recently bought and sold shares of the business. ANTIPODES PARTNERS Ltd bought a new position in SiBone in the fourth quarter worth approximately $29,000. Versant Capital Management Inc boosted its position in SiBone by 102.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company's stock valued at $29,000 after acquiring an additional 887 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of SiBone by 98.5% in the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company's stock valued at $29,000 after acquiring an additional 736 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in SiBone by 64,700.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company's stock valued at $38,000 after acquiring an additional 1,941 shares in the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in SiBone during the 4th quarter valued at about $53,000. 98.11% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several equities research analysts have issued reports on the stock. UBS Group boosted their price objective on shares of SiBone from $24.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. Truist Financial reaffirmed a "buy" rating and set a $23.00 target price (up from $21.00) on shares of SiBone in a research report on Tuesday, August 4th. Weiss Ratings raised shares of SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 20th. Finally, TD Cowen boosted their price target on SiBone from $18.00 to $20.00 and gave the company a "buy" rating in a report on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $24.17.
Check Out Our Latest Stock Report on SiBone
About SiBone
(
Get Free Report)
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
